[go: up one dir, main page]

EP4259065A1 - Silicon-based tetrahydrocannabinol derivatives and compositions thereof - Google Patents

Silicon-based tetrahydrocannabinol derivatives and compositions thereof

Info

Publication number
EP4259065A1
EP4259065A1 EP20835965.3A EP20835965A EP4259065A1 EP 4259065 A1 EP4259065 A1 EP 4259065A1 EP 20835965 A EP20835965 A EP 20835965A EP 4259065 A1 EP4259065 A1 EP 4259065A1
Authority
EP
European Patent Office
Prior art keywords
silicon
tetrahydrocannabinol
derivative according
group
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20835965.3A
Other languages
German (de)
French (fr)
Inventor
Barry C. Arkles
Taewoo Min
Jonathan D. GOFF
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gelest Inc
Original Assignee
Gelest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gelest Inc filed Critical Gelest Inc
Publication of EP4259065A1 publication Critical patent/EP4259065A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0834—Compounds having one or more O-Si linkage
    • C07F7/0838—Compounds with one or more Si-O-Si sequences
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
    • A61K8/585—Organosilicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/89—Polysiloxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/10—General cosmetic use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Definitions

  • Tetrahydrocannabinol is a phytocannabinoid which is known to have antiinflammatory activity. It is the primary psychoactive cannabinoid and is known to bind to cannabinoid receptors (CB 1 and CB2) to reduce pain, inflammation, and hyperalgesia (see, for example, Citti et al, Sci. Rep. 9, 20335 (2019); Karsak et al, Science, 316,1494 (2007);
  • Tetrahydrocannabinol is the designated name for (6a7?,10a7?)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-67/-benzo[c]chromen-l-ol, shown below:
  • a silicon-based tetrahydrocannabinol derivative according to an embodiment of the disclosure contains a silicon-based functional group containing Si-O-Si bonds which is bound to a tetrahydrocannabinol molecule having Formula (I):
  • a topical or dermatological formulation according to an embodiment of the disclosure contains a base formulation and at least one silicon-based tetrahydrocannabinol derivative comprising at least one silicon-based functional group containing Si-O-Si bonds which is bound to a tetrahydrocannabinol molecule having Formula (I):
  • the disclosure relates to compositions containing derivatives of tetrahydrocannabinol (THC) containing a silicon-containing functional group which are beneficial for various applications, including the formulation of topical medicinal products and personal care products, and methods for their preparation.
  • THC tetrahydrocannabinol
  • the silicon-containing tetrahydrocannabinol derivatives described herein are unique hybrid organosilicon compounds formed by attaching tetrahydrocannabinol to a siloxane backbone, also described as a molecule comprising one silicon-based functional group containing Si-O-Si bonds which is bound to a tetrahydrocannabinol molecule.
  • cannabinoid acceptors of the compounds described herein has not yet been studied, they are expected to provide increased stability and solubility and to release the free tetrahydrocannabinol uniformly and over a prolonged period.
  • tetrahydrocannabinol and THC are intended to encompass all isomers of tetrahydrocannabinol, including those found naturally or developed synthetically.
  • Preferred embodiments of the compounds of the disclosure include trisiloxanyl derivatives of tetrahydrocannabinol in which a siloxane-based group is bound through the phenolic hydroxyl group of the tetrahydrocannabinol molecule, forming an Si-O-C bond.
  • the silicon-based tetrahydrocannabinol derivatives include a tetrahydrocannabinol molecule, such as shown in Formula (I), having a silicon-based group as a functional group. Most preferably, the silicon-based group is a siloxanyl group or a trialkoxysilane- containing group.
  • Preferred tetrahydrocannabinol derivatives described herein have a structure in accordance with Formula (I) above in which the phenolic hydroxyl group is bound to a siloxane moiety containing two or more silicon atoms, preferably three or more silicon atoms, most preferably about 3 to about 10 silicon atoms.
  • Tetrahydrocannabinol derivatives according to embodiments of the invention have general formula (A).
  • R may be, for example and without limitation, SiMe(OSiMe 3 )2, SiMe2(OSiMe2)4CH2CH2CH 2 CH3, SiMe 2 OSiMe3, and SiMe 2 OSiMe2C 6 H5, in which “Me” is a methyl group.
  • compounds having formula (A) that are within the scope of the disclosure are not limited to these substituents, and other silicon-containing functional groups having Si-O-Si bonds that are known in the art or to be developed would also be suitable for R.
  • Substituents containing a single silicon atom without an oxane (oxygen) bridge between two or more silicon atoms are not within the scope of the disclosure because such tetrahydrocannabinol derivatives fail to provide acceptable film-forming properties.
  • simple trialkylsilyl derivatives, as well as derivatives containing only alkyl, aryl, hydrogen, halogen, vinyl, allyl and/or alkoxy substituents on the silicon are not within the scope of the disclosure as these are not effective for the intended purpose.
  • Other compounds within the scope of the disclosure include polydimethylsiloxanes in which the tetrahydrocannabinol substitutes through the phenolic oxygen in place of a methyl group on a polydimethylsiloxane, such as Me3Si(OSiMe2)m(OSiMeTHC)nSiMe3, in which “THC” represents tetrahydrocannabinol, Me is a methyl group, and m and n are integers.
  • m is 1 to about 100 and n is 1 to about 10.
  • the silicon-based tetrahydrocannabinol derivatives according to embodiments of the disclosure include a wide variety of derivatized compounds, including most preferred compounds such as, for example, (tetrahydrocannabinoloxy)heptamethyltrisiloxane (formula (II)), tetrahydrocannabinoloxy-terminated polydimethylsiloxane (formula (III)), and tetrahydrocannabinoloxypropyl-terminated polydimethylsiloxane (formula (IV)), shown below, in which m and n are integers; preferably m is 1 to about 100 and n is 1 to about 10.
  • Compounds according to embodiments of the disclosure may contain a direct ether linkage between the silicon-containing functional group and the phenolic hydroxyl group of the tetrahydrocannabinol molecule (direct Si-0 bond) or may contain an alkyl group spacer between the phenolic hydroxyl group on tetrahydrocannabinol and the silicon-based functional group, such as compounds in which R in formula (A) is CfbSiNfeOSiMes or CfbSiNfeOSiNfeCeHs.
  • the spacer is not limited to CH2, and may also be a longer alkyl chain containing up to about 11 carbon atoms, such as (CH2)3, which, along with CH2, is also a preferred embodiment.
  • Compounds according to embodiments of the disclosure which contain an alkyl group spacer between the phenolic hydroxyl group on tetrahydrocannabinol and the silicon-based functional group may have general formula (B) below, in which R’ is a silicon-based group and x is an integer ranging from 1 to about 11, preferably 1 (methyl) to 3 (propyl). Most preferably, the silicon-based group is a siloxanyl group or a trialkoxysilane-containing group.
  • R’ may be, for example and without limitation, SiMe(OSiMe3)2, SiMe2(OSiMe2)4CH2CH2CH2CH3, SiMe2OSiMe3, or SiMe2OSiMe2CeH5, in which Me is methyl.
  • Direct Si-0 linkage of the tetrahydrocannabinol derivatives may result in diminished allergic inflammation by releasing free tetrahydrocannabinol over a prolonged period by slow hydrolysis.
  • the Si-0 bond on tetrahydrocannabinol derivatives is not stable when exposed to moisture, which results in slow decomposition of compounds to form free tetrahydrocannabinol and low molecular weight siloxanes.
  • the silane-based tetrahydrocannabinol derivatives are anticipated to be stable when stored in air and protected from moisture. They are anticipated to show bioactivity in medicinal applications either directly or by slow hydrolysis to form underivatized THC.
  • silicones and silicone derivatives are easily incorporated into topical or dermatological products, including anti-inflammatory and palliative formulations, due to their solubility in a range of polar compounds such as castor oil and a variety of cosmetic or dermatological vehicles. They may also act as co-solvents for silicones. Further, due to such solubility, these derivatives may be useful as compatibilizers for other bioactives, such as unmodified cannabidiol and tetrahydrocannabinol compounds, among other possible applications.
  • the tetrahydrocannabinol derivatives described herein may be prepared by various synthetic pathways.
  • the compounds may be prepared by reacting the hydroxyl group on the benzenoid ring of tetrahydrocannabinol with an allylic halide in a solvent to form an allyloxytetrahydrocannabinol intermediate, and then hydrosilylating the intermediate with a silane compound and catalyst to form a silicon-based tetrahydrocannabinol derivative with a spacer.
  • a direct Si-0 linkage on the hydroxyl group of tetrahydrocannabinol by reacting the hydroxyl group (C-OH) with a chlorine-containing siloxane compound (-Si-Cl) in the presence of a base acceptor, or by the dehydrogenative coupling of the hydroxyl group with a hydride- containing siloxane compound (-Si-H).
  • the silane compounds used in the reactions described above may be any of a wide variety of silicon-based compounds, and preferably include alkylsilanes, alkoxysilanes, alkylsiloxanes and alkoxysiloxanes and their derivatized or functionalized counterparts. In general, it is preferred to have two or more silicon atoms in the substitution in order to provide solubility and spreading characteristics suitable for topical creams and ointments.
  • Examples include, without limitation, bis(trimethylsiloxy)methylsilane, bis(trimethylsiloxy)ethylsilane, bis(trimethylsiloxy)propylsilane, bis(triethylsiloxy)methylsilane, bis(triethylsiloxy)ethylsilane, bis(triethylsiloxy)propylsilane, triethoxysilane, trimethoxysilane, tripropylsilane, bis(tripropylsiloxy)methylsilane, bis(tripropylsiloxy)ethylsilane, bis(tripropylsiloxy)propylsilane and similar compounds.
  • silane compounds herein are polymeric silicon-containing molecules having similar reactive capabilities as the silane monomeric structures noted above, such as polydimethylsiloxane, polydiethylsiloxane, poly dipropyl siloxane, polymethylethylsilane, polymethylpropylsiloxane, and other polyalkyl- or polyalkenyl-siloxanes as are known in the art or to be developed. Chain lengths may vary, but it is preferred that the molecular weight (Mn) of polymeric silane compounds used to form polymeric silicon-based derivative groups on tetrahydrocannabinol be from 100 to about 5000, and most preferably from about 500 to about 2000.
  • Mn molecular weight
  • the derivatives described herein may be produced using pure tetrahydrocannabinol.
  • the derivatives may be formed and provided as a component of phytocannabinoid and/or other phytochemical mixtures.
  • the tetrahydrocannabinol derivative of cannabis extracts may be formed without isolating the pure tetrahydrocannabinol component.
  • compositions according to the invention may contain one or more of the derivatives described herein and one or more phytochemicals extracted from cannabis.
  • the silicon-based tetrahydrocannabinols described herein may be used in various topical and dermatological compositions, including preferably those which have silicon compounds or silicone-based polymers in the base formulation because the derivatives facilitate compatibility and solubility in such compounds within formulations.
  • the disclosure is not limited to those compositions and may include any topical or dermatological composition in which the silicon-based tetrahydrocannabinol derivatives are useful.
  • the cosmetic and topical compositions of the present disclosure include a base formulation, which may be any suitable topical or dermatological base formulation as described above, and at least one silicon-based tetrahydrocannabinol derivative as described herein.
  • the silicon-based tetrahydrocannabinol derivatives include a tetrahydrocannabinol molecule or a commercial or natural derivative thereof and include a silicon-based functional group bonded to the tetrahydrocannabinol molecule (or the derivative thereof) through the oxygen atom of the benzenoid ring.
  • the silicon-based tetrahydrocannabinol derivative is present in an amount of about 0.01 percent by weight to about 20 percent by weight, preferably about 0.5 percent by weight to about 5 weight percent and most preferably about 0.5 to about 1.0 percent by weight based on the weight of the formulation.
  • reaction mixture is filtered through silica gel (40g) and washed with tetrahydrofuran (400g). The filtrate is concentrated in vacuo. The residue contains the product and unreacted tetrahydrocannabinol and is analyzed by NMR and FTIR.
  • Example 2 Synthesis of 1-butyl-l, 1,3, 3,5,5, 7,7,9,9-decamethyl-9-(((6aR,10aR)-6,6,9-trimethyl- 3 -pentyl-6a,7, 8, 10a-tetrahvdro-6H-benzol clchromen- 1 -yl)oxy)pentasiloxane (III)
  • reaction mixture is filtered through silica gel (40g) and washed with tetrahydrofuran (400g). The filtrate is concentrated in vacuo. The residue contains the product and unreacted tetrahydrocannabinol and is analyzed by NMR and FTIR.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Catalysts (AREA)

Abstract

Silicon-based tetrahydrocannabinol derivatives and methods for their synthesis are provided, in which the derivatives contain a tetrahydrocannabinol molecule and at least one silicon-based group containing Si-O-Si bonds. The derivatives are useful in topical and dermatological compositions, have potential beneficial topical properties, and enhance solubility and compatibility in topical and dermatological formulations containing the silicon-based materials.

Description

TITLE OF THE INVENTION
[0001] Silicon-based Tetrahydrocannabinol Derivatives and Compositions Thereof
BACKGROUND OF THE INVENTION
[0002] Tetrahydrocannabinol (THC) is a phytocannabinoid which is known to have antiinflammatory activity. It is the primary psychoactive cannabinoid and is known to bind to cannabinoid receptors (CB 1 and CB2) to reduce pain, inflammation, and hyperalgesia (see, for example, Citti et al, Sci. Rep. 9, 20335 (2019); Karsak et al, Science, 316,1494 (2007);
Richardson et al, Pain, 75, 111 (1998)). Tetrahydrocannabinol is the designated name for (6a7?,10a7?)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-67/-benzo[c]chromen-l-ol, shown below:
[0003] Topical formulations of tetrahydrocannabinol have been reported to reduce allergic inflammation (Karsak et al, Science, 316, 1494-1497 (2007)). Pure tetrahydrocannabinol has low stability in air, light, acid media, and at high temperature, but derivatives of tetrahydrocannabinol with increased in stability would be attractive. Also desirable would be derivatives having lower surface tension, which would enable the formation of thin films either directly or by enhancing solubility in low surface tension fluids, such as silicones.
BRIEF SUMMARY OF THE INVENTION
[0004] A silicon-based tetrahydrocannabinol derivative according to an embodiment of the disclosure contains a silicon-based functional group containing Si-O-Si bonds which is bound to a tetrahydrocannabinol molecule having Formula (I): [0005] A topical or dermatological formulation according to an embodiment of the disclosure contains a base formulation and at least one silicon-based tetrahydrocannabinol derivative comprising at least one silicon-based functional group containing Si-O-Si bonds which is bound to a tetrahydrocannabinol molecule having Formula (I):
DETAILED DESCRIPTION OF THE INVENTION
[0006] The disclosure relates to compositions containing derivatives of tetrahydrocannabinol (THC) containing a silicon-containing functional group which are beneficial for various applications, including the formulation of topical medicinal products and personal care products, and methods for their preparation. The silicon-containing tetrahydrocannabinol derivatives described herein are unique hybrid organosilicon compounds formed by attaching tetrahydrocannabinol to a siloxane backbone, also described as a molecule comprising one silicon-based functional group containing Si-O-Si bonds which is bound to a tetrahydrocannabinol molecule. Although the binding affinity for cannabinoid acceptors of the compounds described herein has not yet been studied, they are expected to provide increased stability and solubility and to release the free tetrahydrocannabinol uniformly and over a prolonged period.
[0007] As used herein, the terms tetrahydrocannabinol and THC are intended to encompass all isomers of tetrahydrocannabinol, including those found naturally or developed synthetically. [0008] Preferred embodiments of the compounds of the disclosure include trisiloxanyl derivatives of tetrahydrocannabinol in which a siloxane-based group is bound through the phenolic hydroxyl group of the tetrahydrocannabinol molecule, forming an Si-O-C bond.
[0009] The silicon-based tetrahydrocannabinol derivatives include a tetrahydrocannabinol molecule, such as shown in Formula (I), having a silicon-based group as a functional group. Most preferably, the silicon-based group is a siloxanyl group or a trialkoxysilane- containing group. [0010] Preferred tetrahydrocannabinol derivatives described herein have a structure in accordance with Formula (I) above in which the phenolic hydroxyl group is bound to a siloxane moiety containing two or more silicon atoms, preferably three or more silicon atoms, most preferably about 3 to about 10 silicon atoms.
[0011] Tetrahydrocannabinol derivatives according to embodiments of the invention have general formula (A). In this formula, R may be, for example and without limitation, SiMe(OSiMe3)2, SiMe2(OSiMe2)4CH2CH2CH2CH3, SiMe2OSiMe3, and SiMe2OSiMe2C6H5, in which “Me” is a methyl group. However, compounds having formula (A) that are within the scope of the disclosure are not limited to these substituents, and other silicon-containing functional groups having Si-O-Si bonds that are known in the art or to be developed would also be suitable for R.
[0012] Substituents containing a single silicon atom without an oxane (oxygen) bridge between two or more silicon atoms are not within the scope of the disclosure because such tetrahydrocannabinol derivatives fail to provide acceptable film-forming properties. For example, simple trialkylsilyl derivatives, as well as derivatives containing only alkyl, aryl, hydrogen, halogen, vinyl, allyl and/or alkoxy substituents on the silicon are not within the scope of the disclosure as these are not effective for the intended purpose.
[0013] Other compounds within the scope of the disclosure include polydimethylsiloxanes in which the tetrahydrocannabinol substitutes through the phenolic oxygen in place of a methyl group on a polydimethylsiloxane, such as Me3Si(OSiMe2)m(OSiMeTHC)nSiMe3, in which “THC” represents tetrahydrocannabinol, Me is a methyl group, and m and n are integers. Preferably, m is 1 to about 100 and n is 1 to about 10.
[0014] The silicon-based tetrahydrocannabinol derivatives according to embodiments of the disclosure include a wide variety of derivatized compounds, including most preferred compounds such as, for example, (tetrahydrocannabinoloxy)heptamethyltrisiloxane (formula (II)), tetrahydrocannabinoloxy-terminated polydimethylsiloxane (formula (III)), and tetrahydrocannabinoloxypropyl-terminated polydimethylsiloxane (formula (IV)), shown below, in which m and n are integers; preferably m is 1 to about 100 and n is 1 to about 10.
[0015] Compounds according to embodiments of the disclosure may contain a direct ether linkage between the silicon-containing functional group and the phenolic hydroxyl group of the tetrahydrocannabinol molecule (direct Si-0 bond) or may contain an alkyl group spacer between the phenolic hydroxyl group on tetrahydrocannabinol and the silicon-based functional group, such as compounds in which R in formula (A) is CfbSiNfeOSiMes or CfbSiNfeOSiNfeCeHs. The spacer is not limited to CH2, and may also be a longer alkyl chain containing up to about 11 carbon atoms, such as (CH2)3, which, along with CH2, is also a preferred embodiment.
[0016] Compounds according to embodiments of the disclosure which contain an alkyl group spacer between the phenolic hydroxyl group on tetrahydrocannabinol and the silicon-based functional group may have general formula (B) below, in which R’ is a silicon-based group and x is an integer ranging from 1 to about 11, preferably 1 (methyl) to 3 (propyl). Most preferably, the silicon-based group is a siloxanyl group or a trialkoxysilane-containing group. R’ may be, for example and without limitation, SiMe(OSiMe3)2, SiMe2(OSiMe2)4CH2CH2CH2CH3, SiMe2OSiMe3, or SiMe2OSiMe2CeH5, in which Me is methyl.
[0017] Direct Si-0 linkage of the tetrahydrocannabinol derivatives, such as shown in formula (A), may result in diminished allergic inflammation by releasing free tetrahydrocannabinol over a prolonged period by slow hydrolysis. The Si-0 bond on tetrahydrocannabinol derivatives is not stable when exposed to moisture, which results in slow decomposition of compounds to form free tetrahydrocannabinol and low molecular weight siloxanes. The silane-based tetrahydrocannabinol derivatives are anticipated to be stable when stored in air and protected from moisture. They are anticipated to show bioactivity in medicinal applications either directly or by slow hydrolysis to form underivatized THC.
[0018] Unlike many silicones and silicone derivatives, these compounds are easily incorporated into topical or dermatological products, including anti-inflammatory and palliative formulations, due to their solubility in a range of polar compounds such as castor oil and a variety of cosmetic or dermatological vehicles. They may also act as co-solvents for silicones. Further, due to such solubility, these derivatives may be useful as compatibilizers for other bioactives, such as unmodified cannabidiol and tetrahydrocannabinol compounds, among other possible applications.
[0019] The tetrahydrocannabinol derivatives described herein may be prepared by various synthetic pathways. In accordance with one embodiment of the disclosure, the compounds may be prepared by reacting the hydroxyl group on the benzenoid ring of tetrahydrocannabinol with an allylic halide in a solvent to form an allyloxytetrahydrocannabinol intermediate, and then hydrosilylating the intermediate with a silane compound and catalyst to form a silicon-based tetrahydrocannabinol derivative with a spacer. It is also within the scope of this disclosure to form a direct Si-0 linkage on the hydroxyl group of tetrahydrocannabinol by reacting the hydroxyl group (C-OH) with a chlorine-containing siloxane compound (-Si-Cl) in the presence of a base acceptor, or by the dehydrogenative coupling of the hydroxyl group with a hydride- containing siloxane compound (-Si-H). Another possible synthetic route to form the direct Si-0 linkage is the formation of an alkali metal alkoxide intermediate (-C-O-Na) and reacting the intermediate with either a Si-Cl or Si-H containing siloxane compound. Reaction to form a hydrocarbon bridge proceeds by the addition of a hydride containing siloxane (-Si — H) across a C=C double bond by a hydrosilylation reaction.
[0020] The silane compounds used in the reactions described above may be any of a wide variety of silicon-based compounds, and preferably include alkylsilanes, alkoxysilanes, alkylsiloxanes and alkoxysiloxanes and their derivatized or functionalized counterparts. In general, it is preferred to have two or more silicon atoms in the substitution in order to provide solubility and spreading characteristics suitable for topical creams and ointments. Examples include, without limitation, bis(trimethylsiloxy)methylsilane, bis(trimethylsiloxy)ethylsilane, bis(trimethylsiloxy)propylsilane, bis(triethylsiloxy)methylsilane, bis(triethylsiloxy)ethylsilane, bis(triethylsiloxy)propylsilane, triethoxysilane, trimethoxysilane, tripropylsilane, bis(tripropylsiloxy)methylsilane, bis(tripropylsiloxy)ethylsilane, bis(tripropylsiloxy)propylsilane and similar compounds.
[0021] Also useful as silane compounds herein are polymeric silicon-containing molecules having similar reactive capabilities as the silane monomeric structures noted above, such as polydimethylsiloxane, polydiethylsiloxane, poly dipropyl siloxane, polymethylethylsilane, polymethylpropylsiloxane, and other polyalkyl- or polyalkenyl-siloxanes as are known in the art or to be developed. Chain lengths may vary, but it is preferred that the molecular weight (Mn) of polymeric silane compounds used to form polymeric silicon-based derivative groups on tetrahydrocannabinol be from 100 to about 5000, and most preferably from about 500 to about 2000. It should be noted that variations in molecular weight above and below this range are within the scope of the disclosure and that the components having different chain lengths may contribute varying properties accordingly. For example, generally, lower molecular weight chains would tend to be more emollient in nature, while higher molecular weight chains would tend to be more substantive in terms of being longer-wearing on skin and more resistant to wash- off.
[0022] It should also be understood that the derivatives described herein may be produced using pure tetrahydrocannabinol. Alternatively, the derivatives may be formed and provided as a component of phytocannabinoid and/or other phytochemical mixtures. For example, the tetrahydrocannabinol derivative of cannabis extracts may be formed without isolating the pure tetrahydrocannabinol component. Further, compositions according to the invention may contain one or more of the derivatives described herein and one or more phytochemicals extracted from cannabis.
[0023] The silicon-based tetrahydrocannabinols described herein may be used in various topical and dermatological compositions, including preferably those which have silicon compounds or silicone-based polymers in the base formulation because the derivatives facilitate compatibility and solubility in such compounds within formulations. However, the disclosure is not limited to those compositions and may include any topical or dermatological composition in which the silicon-based tetrahydrocannabinol derivatives are useful. The cosmetic and topical compositions of the present disclosure include a base formulation, which may be any suitable topical or dermatological base formulation as described above, and at least one silicon-based tetrahydrocannabinol derivative as described herein. The silicon-based tetrahydrocannabinol derivatives include a tetrahydrocannabinol molecule or a commercial or natural derivative thereof and include a silicon-based functional group bonded to the tetrahydrocannabinol molecule (or the derivative thereof) through the oxygen atom of the benzenoid ring.
[0024] When incorporated in such formulations, it is preferred that the silicon-based tetrahydrocannabinol derivative is present in an amount of about 0.01 percent by weight to about 20 percent by weight, preferably about 0.5 percent by weight to about 5 weight percent and most preferably about 0.5 to about 1.0 percent by weight based on the weight of the formulation.
[0025] The invention will now be described in connection with the following, non-limiting examples.
Example 1 : Synthesis of 1.1.1.3,5,5,5-heptamethyl-3-(((6aR.10aR)-6,6,9-trimethyl-3-pentyl- 6a.7.8.10a-tetrahydro-6H-benzo[ clchromen- 1 -yl)oxy)trisiloxane (II)
[0026] Sodium (0.55g, 0.02 mol) and tetrahydrofuran (13.42g) are charged to a reactor. A solution of tetrahydrocannabinol (6.29g, 0.02 mol) in tetrahydrofuran (37.98g) is added dropwise over 30 min while keeping pot temperature below 70 °C. The resulting reaction mixture is stirred at 50-60 °C until all sodium has been consumed. Bis(trimethylsiloxy)methylsilane (6.77g, 0.03 mol) is added dropwise over 10 min at 70 °C, then the reaction mixture is heated at 110-120 °C for lOh. The reaction mixture is filtered through silica gel (40g) and washed with tetrahydrofuran (400g). The filtrate is concentrated in vacuo. The residue contains the product and unreacted tetrahydrocannabinol and is analyzed by NMR and FTIR.
Example 2: Synthesis of 1-butyl-l, 1,3, 3,5,5, 7,7,9,9-decamethyl-9-(((6aR,10aR)-6,6,9-trimethyl- 3 -pentyl-6a,7, 8, 10a-tetrahvdro-6H-benzol clchromen- 1 -yl)oxy)pentasiloxane (III)
[0027] Sodium (0.55g, 0.02 mol) and tetrahydrofuran (13.42g) are charged to a reactor. A solution of tetrahydrocannabinol (6.29g, 0.02 mol) in tetrahydrofuran (37.98g) is added dropwise over 30 min while keeping pot temperature below 70 °C. The resulting reaction mixture is stirred at 50-60 °C until all sodium has been consumed. l-Butyl-1,1,3,3,5,5,7,7,9,9- decamethylpentasiloxane (12.39g, 0.03 mol) is added dropwise over 10 min at 70 °C, then the reaction mixture is heated at 110-120 °C for lOh. The reaction mixture is filtered through silica gel (40g) and washed with tetrahydrofuran (400g). The filtrate is concentrated in vacuo. The residue contains the product and unreacted tetrahydrocannabinol and is analyzed by NMR and FTIR.
Example 3: Tetrahydrocannabinoloxypropyl-terminated polydimethylsiloxane (IV)
[0028] Allyloxytetrahydrocannabinol (70.9g, 0.2 mol) and toluene (50mL) are charged to a reactor. The resulting mixture is heated to 80-90 °C. Karstedt catalyst (2% Pt concentration in xylene, 0.5 mL) is added when pot temperature reaches 80-90 °C. Hydride-terminated poly dimethylsiloxane (Mn-1050, 105g) is added dropwise while controlling the exotherm, then the reaction mixture is heated at 85-115 °C until FTIR indicates that all Si-H has been consumed. Activated charcoal is added to the mixture and stirred overnight. The mixture is filtered and the filtrate is concentrated in vacuo. The residue contains the product and unreacted tetrahydrocannabinol and is analyzed by XH NMR and FTIR.
[0029] It will be appreciated by those skilled in the art that changes could be made to the embodiment described above without departing from the broad inventive concepts thereof. Also, based on this disclosure, a person of ordinary skill in the art would further recognize that the relative proportions of the components illustrated above could be varied without departing from the spirit and scope of the invention. It is understood, therefore, that this invention is not limited to that particular embodiment disclosed, but it is intended to cover modifications within the spirit and scope of the present invention as defined by the appended claims.

Claims

CLAIMS We claim:
1. A silicon-based tetrahydrocannabinol derivative comprising a silicon-based functional group containing Si-O-Si bonds which is bound to a tetrahydrocannabinol molecule having formula (I):
2. The silicon-based tetrahydrocannabinol derivative according to claim 1, wherein the silicon-based functional group is bound to the tetrahydrocannabinol molecule by a phenolic oxygen atom in the benzenoid ring.
3 The silicon-based tetrahydrocannabinol derivative according to claim 1, wherein the silicon-based functional group is a siloxanyl group or a trialkoxysilane-containing group.
4. The silicon-based tetrahydrocannabinol derivative according to claim 1, wherein the silicon-based functional group contains at least two silicon atoms.
5. The silicon-based tetrahydrocannabinol derivative according to claim 1, having formula (A), wherein R is SiMe(OSiMe3)2, SiMe2(OSiMe2)4CH2CH2CH2CH3, SiMe2OSiMe3, SiMe2OSiMe2CeH5, CH2SiMe2OSiMe3 or CH2SiMe2OSiMe2CeH5, and wherein Me represents a methyl group:
6. The silicon-based tetrahydrocannabinol derivative according to claim 1, having formula (B), wherein R’ is SiMe(OSiMe3)2, SiMe2(OSiMe2)4CH2CH2CH2CH3, SiMe2OSiMe3, or SiMe2OSiMe2CeH5, Me represents a methyl group, and x is an integer ranging from 1 to about 11 :
7. The silicon-based tetrahydrocannabinol derivative according to claim 1, having formula (II), wherein Me represents a methyl group:
8. The silicon-based tetrahydrocannabinol derivative according to claim 1, having formula (III):
9. The silicon-based tetrahydrocannabinol derivative according to claim 1, having formula (IV), wherein Me represents a methyl group, m is an integer from 1 to about 100, and n is an integer from 1 to about 10:
10. A topical or dermatological composition comprising a base formulation and at least one silicon-based tetrahydrocannabinol derivative, wherein the at least one silicon-based tetrahydrocannabinol derivative comprises a silicon-based functional group containing Si-O-Si bonds which is bound to a tetrahydrocannabinol molecule having formula (I):
11. The topical or dermatological composition according to claim 10, wherein the silicon- based functional group is bound to the tetrahydrocannabinol molecule by a phenolic oxygen atom in the benzenoid ring.
12. The topical or dermatological composition according to claim 10, wherein the silicon- based functional group is a siloxanyl group or a trialkoxysilane-containing group.
13. The topical or dermatological composition according to claim 10, wherein the silicon- based functional group contains at least two silicon atoms.
14. A method for making the silicon-based tetrahydrocannabinol derivative according to claim 1, comprising reacting tetrahydrocannabinol with an allylic halide in a solvent to form an allyloxytetrahydrocannabinol intermediate, and reacting the allyloxytetrahydrocannabinol intermediate with a silane compound and a catalyst to form the silicon-based tetrahydrocannabinol derivative.
15. A method for making the silicon-based tetrahydrocannabinol derivative according to claim 1, comprising forming a silylated alkyl ether on a tetrahydrocannabinol molecule by reacting a chlorine-containing siloxane compound with a hydroxyl group in the presence of a base acceptor.
16. A method for making the silicon-based tetrahydrocannabinol derivative according to claim 1, comprising forming a silylated alkyl ether on a tetrahydrocannabinol molecule by dehydrogenative coupling of a hydride-containing siloxane.
17. A method for making the silicon-based tetrahydrocannabinol derivative according to claim 1, comprising forming a silylated alkyl ether on a tetrahydrocannabinol molecule by forming an intermediate alkali metal alkoxide followed by reaction with a silicon-hydride or silicon-chlorine containing compound.
18. A composition comprising the silicon-based tetrahydrocannabinol derivative according to claim 1 and at least one phytochemical extracted from cannabis.
EP20835965.3A 2020-12-10 2020-12-10 Silicon-based tetrahydrocannabinol derivatives and compositions thereof Pending EP4259065A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2020/064235 WO2022125095A1 (en) 2020-12-10 2020-12-10 Silicon-based tetrahydrocannabinol derivatives and compositions thereof

Publications (1)

Publication Number Publication Date
EP4259065A1 true EP4259065A1 (en) 2023-10-18

Family

ID=74125705

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20835965.3A Pending EP4259065A1 (en) 2020-12-10 2020-12-10 Silicon-based tetrahydrocannabinol derivatives and compositions thereof

Country Status (6)

Country Link
EP (1) EP4259065A1 (en)
JP (1) JP7637241B2 (en)
KR (1) KR20230143137A (en)
CN (1) CN116685595A (en)
CA (1) CA3201704A1 (en)
WO (1) WO2022125095A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4471038A1 (en) * 2023-05-30 2024-12-04 Tresco Holding GmbH Process for the synthesis of tetrahydrocannabinolic acid dimethylsiloxane, and tetrahydrocannabinolic acid dimethylsiloxane

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292899A (en) * 1991-11-27 1994-03-08 Synthetic Technology Corporation Synthesis of 11-nor-Δ-9-tetrahydrocannabinol-9-carboxylic acid glucuronide
FR2854896B1 (en) * 2003-05-16 2007-08-17 Mayoly Spindler Lab NOVEL SURFACTANTS, COMPOSITIONS COMPRISING SAME
US8293786B2 (en) * 2007-07-30 2012-10-23 Alltranz Inc. Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same
CA2705132C (en) * 2007-11-30 2017-09-26 Alltranz Inc. Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same
WO2018148785A1 (en) * 2017-02-15 2018-08-23 Botanix Pharmaceuticals Ltd Formulations of cannabinoids for the treatment of dermatitis and inflammatory skin diseases
WO2018148787A1 (en) * 2017-02-15 2018-08-23 Botanix Pharmaceuticals Ltd Formulations of cannabinoids for the treatment of psoriasis
WO2020214574A1 (en) * 2019-04-15 2020-10-22 Trustees Of Boston University One-step flow-mediated synthesis of cannabidiol (cbd) and derivatives
CN112047973B (en) * 2019-06-06 2022-11-18 上海科技大学 Cannabinoids compound, preparation method, composition and application thereof

Also Published As

Publication number Publication date
JP7637241B2 (en) 2025-02-27
CA3201704A1 (en) 2022-06-16
KR20230143137A (en) 2023-10-11
JP2023554329A (en) 2023-12-27
WO2022125095A1 (en) 2022-06-16
CN116685595A (en) 2023-09-01

Similar Documents

Publication Publication Date Title
JP2777058B2 (en) Organosilicon compound and production method thereof
JP2014502271A5 (en)
KR19990088673A (en) Carbosiloxane dendrimers
FI94031C (en) Rhodium colloid, method of its preparation and its use
AU628064B2 (en) Diorganopolysiloxane derivatives, their preparation and their use
EP0661331B1 (en) Silicon-containing polymer, process for preparing the same and monomer thereof
EP3154992A1 (en) Platinum catalyzed hydrosilylation reactions utilizing cyclodiene additives
JP7637241B2 (en) Silicon-Based Tetrahydrocannabinol Derivatives and Compositions Thereof
US5539137A (en) Aryl substituted silicone fluids having high refractive indices and method for making
EP2632905A1 (en) Process for preparing 2-hydroxyphenyl benzotriazole siloxane compounds
EP4410796A1 (en) Method for producing alkoxysilyl alkylaminopropyl-modified polysiloxane compound
CA2210586A1 (en) Cyclic silane esters and solvolysis products thereof, and processes for the preparation of the cyclic silane esters and the solvolysis products
US11667655B2 (en) Silicon-based tetrahydrocannabinol derivatives and compositions thereof
CA2084733A1 (en) Siloxy-functional cyclopolysiloxanes
US5086127A (en) Silicone UV absorbers containing silane units
US5693735A (en) Trimethylsiloxy group-containing polysiloxane and a process for producing the same
EP0586241B1 (en) Azasilacycloalkyl functional alkoxysilanes and azasilacycloalkyl functional tetramethyldisiloxanes
US3529007A (en) New organosilicon compounds,their preparation and their use
CA2064379A1 (en) Process for the manufacture of certain new silicone polyether copolymers for polyurethane foam manufacture
CA2152720A1 (en) Organosilicon compounds containing furanyl groups
US4623741A (en) Chlorosilane compounds
JP7156759B2 (en) Silicon-based cannabidiol derivatives and compositions thereof
WO2013191955A1 (en) Monofunctional organopolysiloxanes for compatabilzing polyheterosiloxanes
US6118014A (en) Organofunctional cocyclic siloxanes
Lakhtin et al. Reactions of Trichlorogermane and Trimethylgermane Etherates with 1, 3-Divinyl-1, 1, 3, 3-tetramethyldisiloxane

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230628

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20241016